# SKB264 Plus Glecirasib in Advanced KRAS G12C-Mutant NSCLC: A Phase II Study

> **NCT07670013** · PHASE2 · RECRUITING · sponsor: **Second Affiliated Hospital, Zhejiang University, School of Medicine** · enrollment: 43 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** SKB264
- **DRUG:** Goleirex

## Key facts

- **NCT ID:** NCT07670013
- **Lead sponsor:** Second Affiliated Hospital, Zhejiang University, School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2028-01
- **Final completion:** 2028-06
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2026-07-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07670013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07670013, "SKB264 Plus Glecirasib in Advanced KRAS G12C-Mutant NSCLC: A Phase II Study". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07670013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*